Methotrexate

Where the papers sit

23 papers from the last 6 months study methotrexate directly · updated from PubMed 12 Oct 2026

• Rheumatoid Arthritis and Toxicity

  Methotrexate research is linking rheumatoid arthritis benefit to macrophage polarization, STAT3/NF-κB signaling and redox-sensitive synovial delivery. Combination strategies with cannabidiol and engineered peptide conjugates aim to improve local efficacy. Protective studies target oxidative stress, NRF2, ferroptosis and tissue injury in salivary glands, testes and heart. Renal failure remains a major safety concern, underscored by fatal conventional-dose intoxication.

  8 papers · 34.8%

• Drug Delivery and Immune Effects

  Controlled-release hydrogels, nanogels and albumin nanoparticles are being developed to improve methotrexate delivery and redox activity. Immune-focused work examines TNF-α, immunogenicity and glucocorticoid combinations in inflammatory disease. Other studies address electrochemical detection and therapeutic vulnerability in glioma. The cluster has no single biological or clinical direction beyond expanding methotrexate applications.

  7 papers · 30.4%

• Leukemia Delivery and Mucositis

  Oral cryotherapy and photobiomodulation are being evaluated to reduce methotrexate-associated oral mucositis and preserve quality of life in children with acute lymphoblastic leukemia. Precision delivery approaches target the blood-brain barrier and combine methotrexate with curcumin for leukemia treatment. Endocytosis and local or oral administration recur as delivery themes. A bullous pemphigoid mortality study falls outside this subject, making the cluster heterogeneous.

  5 papers · 21.7%

• CNS Prophylaxis in Lymphoma

  High-dose methotrexate is being tested and refined for preventing central nervous system relapse in high-risk diffuse large B-cell lymphoma. Randomized and international multicenter studies focus on CNS relapse, overall response and treatment toxicity, especially neutropenia. Primary CNS lymphoma regimens combine methotrexate with rituximab and thiotepa. The open question is which patients benefit enough from prophylaxis to justify its toxicity.

  3 papers · 13%